INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Clinical trial / 2017

Oral nicotinamide reduced actinic keratosis size and prevented new lesions in organ transplant recipients over six months.

Thirty-eight transplant recipients with actinic keratoses (AKs) were randomly assigned to receive 500 mg daily oral nicotinamide (n=19) or no nicotinamide (n=19) for six months. At baseline, AK size did not differ significantly between groups. After six months, AKs significantly decreased in size in 18 of 19 treated patients (88%), with complete clinical regression in seven patients (42%) and no new AKs. In contrast, 91% of controls showed increased AK size and/or developed new AKs, and seven pre-existing AKs progressed to squamous-cell carcinoma.

Study type
Randomized controlled trial
Who was studied
38 organ transplant recipients (8 liver, 30 kidney) with single or multiple actinic keratoses
What was measured
Change in actinic keratosis size, complete regression, development of new actinic keratoses, and progression to squamous-cell carcinoma

THE PAPER

Prevention of non-melanoma skin cancers with nicotinamide in transplant recipients: a case-control study.

Drago F, Ciccarese G, Cogorno L, Calvi C, Marsano LA, Parodi A. Eur J Dermatol, 2017.

PubMed 28468736 ↗DOI 10.1684/ejd.2017.3025 ↗

CancerNutrients & adequacy

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.